Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review

J Comput Assist Tomogr. 2011 May-Jun;35(3):387-93. doi: 10.1097/RCT.0b013e318219f810.

Abstract

Objective: This study was designed to review the emerging role of fluorine 18 fluorodeoxyglucose (¹⁸F-FDG)-positron emission tomography (PET) CT/computed tomography (PET/CT) in patients with mycobacteriosis.

Methods: A comprehensive literature search of published studies through October 2010 in PubMed/MEDLINE database regarding ¹⁸F-FDG-PET and PET/CT in patients with mycobacteriosis was performed.

Results: Ultimately, we identified 16 studies comprising a total of 220 patients with mycobacteriosis. Main findings of the included studies are presented.

Conclusions: (1) Mycobacteriosis commonly causes increased ¹⁸F-FDG uptake; therefore, positive ¹⁸F-FDG-PET results should be interpreted with caution in differentiating benign from malignant abnormalities. (2) ¹⁸F-FDG-PET and PET/CT are potentially useful in detecting sites of Mycobacterium infection. (3) Dual-phase ¹⁸F-FDG-PET is not useful for the differential diagnosis between malignant lesions and sites of Mycobacterium infection. (4) ¹⁸F-FDG-PET and PET/CT are useful for the evaluation of disease activity and in monitoring response to therapy in patients with mycobacteriosis. (5) Dual-tracer PET and PET/CT are potentially useful for presumptive diagnosis of solitary pulmonary nodules.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Mycobacterium Infections / diagnostic imaging*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed / methods*
  • Tuberculosis / diagnostic imaging*
  • Tuberculosis / microbiology

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18